Top

Published in:

01-06-2020 | Kidney Cancer | Brief Report

ALK-rearranged renal cell carcinoma with a novel PLEKHA7-ALK translocation and metanephric adenoma-like morphology

Authors: Jen-Fan Hang, Hsiao-Jen Chung, Chin-Chen Pan

Published in: Virchows Archiv | Issue 6/2020

Abstract

ALK-rearranged renal cell carcinoma is a provisional entity in the 2016 WHO Classification of Tumors of the Urinary System and Male Genital Organs. The reported fusion partners included VCL, TPM3, EML4, STRN, and HOOK1. Herein, we present a peculiar renal cell carcinoma morphologically resembling metanephric adenoma and harboring a novel PLEKHA7-ALK fusion. Microscopically, the tumor is composed of bland epithelial cells with scant to moderate amount of amphophilic cytoplasm, round and uniform nuclei, delicate chromatin, and inconspicuous nucleoli, arranged in tightly packed small acini and angulated tubules. Papillary formation, intraluminal glomeruloid tufts, microcysts, and solid nests were focally observed. Psammomatous calcifications were evident. The tumor cells were diffusely reactive for CK7, AMACR, PAX8, and ALK, while non-reactive for WT1, BRAF V600E, CD57, carbonic anhydrase IX, TFE3, and cathepsin K. Fluorescence in situ hybridization showed breaking apart of ALK. A novel PLEKHA7exon18-ALKexon20 fusion was detected using ArcherDX FusionPlex next-generation sequencing panel and was further confirmed with reverse-transcriptase PCR. Our case demonstrates that in contrast to prior cases showing high-grade tumor cells, ALK-rearranged renal cell carcinoma may also present as a low-grade renal tumor mimicking metanephric adenoma. Immunohistochemistry and molecular testing are helpful to identify this tumor, which may be eligible for ALK inhibitor-targeted therapy.

Debelenko LV, Raimondi SC, Daw N, Shivakumar BR, Huang D, Nelson M, Bridge JA (2011) Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum. Mod Pathol 24(3):430–442. https://doi.org/10.1038/modpathol.2010.213 CrossRefPubMed

Marino-Enriquez A, Ou WB, Weldon CB, Fletcher JA, Perez-Atayde AR (2011) ALK rearrangement in sickle cell trait-associated renal medullary carcinoma. Genes Chromosom Cancer 50(3):146–153. https://doi.org/10.1002/gcc.20839 CrossRefPubMed

Sugawara E, Togashi Y, Kuroda N, Sakata S, Hatano S, Asaka R, Yuasa T, Yonese J, Kitagawa M, Mano H, Ishikawa Y, Takeuchi K (2012) Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method. Cancer 118(18):4427–4436. https://doi.org/10.1002/cncr.27391 CrossRefPubMed

Sukov WR, Hodge JC, Lohse CM, Akre MK, Leibovich BC, Thompson RH, Cheville JC (2012) ALK alterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcome in a large series of consecutively treated patients. Mod Pathol 25(11):1516–1525. https://doi.org/10.1038/modpathol.2012.107 CrossRefPubMed

Hodge JC, Pearce KE, Sukov WR (2013) Distinct ALK-rearranged and VCL-negative papillary renal cell carcinoma variant in two adults without sickle cell trait. Mod Pathol 26(4):604–605. https://doi.org/10.1038/modpathol.2012.144 CrossRefPubMed

Srigley JR, Delahunt B, Eble JN, Egevad L, Epstein JI, Grignon D, Hes O, Moch H, Montironi R, Tickoo SK, Zhou M, Argani P, ISUP Renal Tumor Panel (2013) The International Society of Urological Pathology (ISUP) Vancouver classification of renal Neoplasia. Am J Surg Pathol 37(10):1469–1489. https://doi.org/10.1097/PAS.0b013e318299f2d1 CrossRefPubMed

Moch H, Amin MB, Argani P et al (2016) Emerging/provisional renal cell carcinomas. In: Moch H, Humphrey PA, Ulbright TM, Reuter VE (eds) WHO classification of Tumours of the urinary system and male genital organs, 4th edn. IARC, Lyon, p 16

Lee C, Park JW, Suh JH, Nam KH, Moon KC (2013) ALK-positive renal cell carcinoma in a large series of consecutively resected Korean renal cell carcinoma patients. Korean J Pathol 47(5):452–457. https://doi.org/10.4132/KoreanJPathol.2013.47.5.452 CrossRefPubMedPubMedCentral

Smith NE, Deyrup AT, Marino-Enriquez A et al (2014) VCL-ALK renal cell carcinoma in children with sickle-cell trait: the eighth sickle-cell nephropathy? Am J Surg Pathol 38(6):858–863. https://doi.org/10.1097/PAS.0000000000000179 CrossRefPubMedPubMedCentral

10.

Kusano H, Togashi Y, Akiba J, Moriya F, Baba K, Matsuzaki N, Yuba Y, Shiraishi Y, Kanamaru H, Kuroda N, Sakata S, Takeuchi K, Yano H (2016) Two cases of renal cell carcinoma harboring a novel STRN-ALK fusion gene. Am J Surg Pathol 40(6):761–769. https://doi.org/10.1097/PAS.0000000000000610 CrossRefPubMed

11.

Cajaiba MM, Jennings LJ, Rohan SM, Perez-Atayde AR, Marino-Enriquez A, Fletcher JA, Geller JI, Leuer KM, Bridge JA, Perlman EJ (2016) ALK-rearranged renal cell carcinomas in children. Genes Chromosom Cancer 55(5):442–451. https://doi.org/10.1002/gcc.22346 CrossRefPubMed

12.

Cajaiba MM, Jennings LJ, George D, Perlman EJ (2016) Expanding the spectrum of ALK-rearranged renal cell carcinomas in children: identification of a novel HOOK1-ALK fusion transcript. Genes Chromosom Cancer 55(10):814–817. https://doi.org/10.1002/gcc.22382 CrossRefPubMed

13.

Chen YB, Xu J, Skanderup AJ, Dong Y, Brannon AR, Wang L, Won HH, Wang PI, Nanjangud GJ, Jungbluth AA, Li W, Ojeda V, Hakimi AA, Voss MH, Schultz N, Motzer RJ, Russo P, Cheng EH, Giancotti FG, Lee W, Berger MF, Tickoo SK, Reuter VE, Hsieh JJ (2016) Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets. Nat Commun 7:13131. https://doi.org/10.1038/ncomms13131 CrossRefPubMedPubMedCentral

14.

Linehan WM, Spellman PT, Ricketts CJ et al (2016) Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med 374(2):135–145. https://doi.org/10.1056/NEJMoa1505917 CrossRefPubMed

15.

Thorner PS, Shago M, Marrano P, Shaikh F, Somers GR (2016) TFE3-positive renal cell carcinomas are not always Xp11 translocation carcinomas: report of a case with a TPM3-ALK translocation. Pathol Res Pract 212(10):937–942. https://doi.org/10.1016/j.prp.2016.07.004 CrossRefPubMed

16.

Jeanneau M, Gregoire V, Desplechain C et al (2016) ALK rearrangements-associated renal cell carcinoma (RCC) with unique pathological features in an adult. Pathol Res Pract 212(11):1064–1066. https://doi.org/10.1016/j.prp.2016.07.015 CrossRefPubMed

17.

Yu W, Wang Y, Jiang Y, Zhang W, Li Y (2017) Genetic analysis and clinicopathological features of ALK-rearranged renal cell carcinoma in a large series of resected Chinese renal cell carcinoma patients and literature review. Histopathology 71(1):53–62. https://doi.org/10.1111/his.13185 CrossRefPubMed

18.

Oyama Y, Nishida H, Kusaba T, Kadowaki H, Arakane M, Daa T, Watanabe D, Akita Y, Sato F, Mimata H, Yokoyama S (2017) A case of anaplastic lymphoma kinase-positive renal cell carcinoma coincident with Hodgkin lymphoma. Pathol Int 67(12):626–631. https://doi.org/10.1111/pin.12592 CrossRefPubMed

19.

Bodokh Y, Ambrosetti D, Kubiniek V, Tibi B, Durand M, Amiel J, Pertuit M, Barlier A, Pedeutour F (2018) ALK-TPM3 rearrangement in adult renal cell carcinoma: report of a new case showing loss of chromosome 3 and literature review. Cancer Gene Ther 221:31–37. https://doi.org/10.1016/j.cancergen.2017.11.010 CrossRef

20.

Pal SK, Bergerot P, Dizman N, Bergerot C, Adashek J, Madison R, Chung JH, Ali SM, Jones JO, Salgia R (2018) Responses to Alectinib in ALK-rearranged papillary renal cell carcinoma. Eur Urol 74(1):124–128. https://doi.org/10.1016/j.eururo.2018.03.032 CrossRefPubMed

21.

Wang XT, Fang R, Ye SB et al (2019) Targeted next-generation sequencing revealed distinct clinicopathologic and molecular features of VCL-ALK RCC: a unique case from an older patient without clinical evidence of sickle cell trait. Pathol Res Pract 215(11):152651. https://doi.org/10.1016/j.prp.2019.152651 CrossRefPubMed

22.

Ge H, Liu K, Juan T, Fang F, Newman M, Hoeck W (2011) FusionMap: detecting fusion genes from next-generation sequencing data at base-pair resolution. Bioinformatics 27(14):1922–1928. https://doi.org/10.1093/bioinformatics/btr310 CrossRefPubMed

23.

Benelli M, Pescucci C, Marseglia G, Severgnini M, Torricelli F, Magi A (2012) Discovering chimeric transcripts in paired-end RNA-seq data by using EricScript. Bioinformatics 28(24):3232–3239. https://doi.org/10.1093/bioinformatics/bts617 CrossRefPubMed

24.

Yoshida MA, Ohyashiki K, Ochi H, Gibas Z, Pontes JE, Prout GR Jr, Huben R, Sandberg AA (1986) Cytogenetic studies of tumor tissue from patients with nonfamilial renal cell carcinoma. Cancer Res 46(4 Pt 2):2139–2147PubMed

25.

Kovacs G, Szucs S, De Riese W, Baumgartel H (1987) Specific chromosome aberration in human renal cell carcinoma. Int J Cancer 40(2):171–178. https://doi.org/10.1002/ijc.2910400208 CrossRefPubMed

26.

Renshaw AA, Zhang H, Corless CL, Fletcher JA, Pins MR (1997) Solid variants of papillary (chromophil) renal cell carcinoma: clinicopathologic and genetic features. Am J Surg Pathol 21(10):1203–1209. https://doi.org/10.1097/00000478-199710000-00011 CrossRefPubMed

27.

Mantoan Padilha M, Billis A, Allende D, Zhou M, Magi-Galluzzi C (2013) Metanephric adenoma and solid variant of papillary renal cell carcinoma: common and distinctive features. Histopathology 62(6):941–953. https://doi.org/10.1111/his.12106 CrossRefPubMed

28.

Kinney SN, Eble JN, Hes O, Williamson SR, Grignon DJ, Wang M, Zhang S, Baldrige LA, Martignoni G, Brunelli M, Wang L, Comperat E, Fan R, Montironi R, MacLennan G, Cheng L (2015) Metanephric adenoma: the utility of immunohistochemical and cytogenetic analyses in differential diagnosis, including solid variant papillary renal cell carcinoma and epithelial-predominant nephroblastoma. Mod Pathol 28(9):1236–1248. https://doi.org/10.1038/modpathol.2015.81 CrossRefPubMed

29.

Argani P (2015) MiT family translocation renal cell carcinoma. Semin Diagn Pathol 32(2):103–113. https://doi.org/10.1053/j.semdp.2015.02.003 CrossRefPubMed

30.

Schrock AB, Zhu VW, Hsieh WS, Madison R, Creelan B, Silberberg J, Costin D, Bharne A, Bonta I, Bosemani T, Nikolinakos P, Ross JS, Miller VA, Ali SM, Klempner SJ, Ou SI (2018) Receptor tyrosine kinase fusions and BRAF kinase fusions are rare but actionable resistance mechanisms to EGFR tyrosine kinase inhibitors. J Thorac Oncol 13(9):1312–1323. https://doi.org/10.1016/j.jtho.2018.05.027 CrossRefPubMed

31.

Pulimeno P, Bauer C, Stutz J, Citi S (2010) PLEKHA7 is an adherens junction protein with a tissue distribution and subcellular localization distinct from ZO-1 and E-cadherin. PLoS One 5(8):e12207. https://doi.org/10.1371/journal.pone.0012207 CrossRefPubMedPubMedCentral

32.

Chung JK, Nocka LM, Decker A, Wang Q, Kadlecek TA, Weiss A, Kuriyan J, Groves JT (2019) Switch-like activation of Bruton's tyrosine kinase by membrane-mediated dimerization. Proc Natl Acad Sci U S A 116(22):10798–10803. https://doi.org/10.1073/pnas.1819309116 CrossRefPubMedPubMedCentral

33.

Li T, Zhang F, Wu Z, Cui L, Zhao X, Wang J, Hu Y (2019) PLEKHM2-ALK: a novel fusion in small-cell lung cancer and durable response to ALK inhibitors. Lung Cancer 139:146–150. https://doi.org/10.1016/j.lungcan.2019.11.002 CrossRefPubMed

34.

Drilon A, Laetsch TW, Kummar S, DuBois S, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, el-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DPS, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, Hong DS, Hyman DM (2018) Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 378(8):731–739. https://doi.org/10.1056/NEJMoa1714448 CrossRefPubMedPubMedCentral

35.

Solomon JP, Hechtman JF (2019) Detection of NTRK fusions: merits and limitations of current diagnostic platforms. Cancer Res 79(13):3163–3168. https://doi.org/10.1158/0008-5472.CAN-19-0372 CrossRefPubMedPubMedCentral

36.

Cai J, Huang X, Yin M, Pan C, Song L, Zhan Z, Chen J, Gao Y, Tang J, Li Y, Shen S (2019) A novel fusion gene PLEKHA6-NTRK3 in langerhans cell histiocytosis. Int J Cancer 144(1):117–124. https://doi.org/10.1002/ijc.31636 CrossRefPubMed

Title: ALK-rearranged renal cell carcinoma with a novel PLEKHA7-ALK translocation and metanephric adenoma-like morphology
Authors: Jen-Fan Hang
Hsiao-Jen Chung
Chin-Chen Pan
Publication date: 01-06-2020
Publisher: Springer Berlin Heidelberg
Keywords: Kidney Cancer
Kidney Cancer
Kidney Cancer
Published in: Virchows Archiv / Issue 6/2020
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-020-02752-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

ALK-rearranged renal cell carcinoma with a novel PLEKHA7-ALK translocation and metanephric adenoma-like morphology

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2020

Histopathological and molecular study for synchronous lung adenocarcinoma staging

Histotype-specific analysis of acid ceramidase expression in ovarian cancer

Higher density of stromal M2 macrophages in breast ductal carcinoma in situ predicts recurrence

Matrix-assisted laser desorption/ionization mass spectrometry imaging to uncover protein alterations associated with the progression of IgA nephropathy

The autopsy debate during the COVID-19 emergency: the Italian experience

Activation of the Akt/mammalian target of rapamycin pathway in combined hepatocellular carcinoma and cholangiocarcinoma: significant correlation between p-4E-BP1 expression in cholangiocarcinoma component and prognosis